Oxford BioMedica plc (OXB.L)
| Previous close | 1,618.00 |
| Open | 1,678.00 |
| Bid | 1,554.00 x 0 |
| Ask | 1,554.00 x 0 |
| Day's range | 1,546.00 - 1,678.00 |
| 52-week range | 774.33 - 1,678.00 |
| Volume | 137,818 |
| Avg. volume | 141,597 |
| Market cap | 1.289B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 70.59 |
| EPS (TTM) | 22.10 |
| Earnings date | 22 Sept 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,600.86 |
- The Independent
Oxford Biomedica revenues double after Covid vaccine contract boost
The gene and cell therapy group saw shares jump on Wednesday after it announced an investment from a vaccine developer.
- Globe Newswire
Oxford Biomedica Plc INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 Oxford Biomedica delivers record first half results Oxford, UK – 22 September 2021: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2021. John Dawson, Oxford Biomedica’s Chief Executive Officer, said: “Everyone at Oxford Biomedica can be truly proud of what they have continued to achieve in 2021. The
- Globe Newswire
Oxford Biomedica announces strategic investment by Serum Life Sciences Ltd
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford Biomedica announces strategic investment by Serum Life Sciences Ltd Oxford, UK
